Norovirus, also known as the stomach flu, affects millions of Americans each year, leading to numerous hospitalizations and even deaths. With no approved treatments available, the focus has shifted towards developing a vaccine to combat this highly contagious virus.
Several companies, including Moderna and Vaxart, are actively working on developing a norovirus vaccine. Moderna, utilizing mRNA technology similar to its successful Covid-19 vaccine, is currently the furthest along in the clinical trial process. Their vaccine targets multiple strains of norovirus, including the predominant GII.4 strain, which has been responsible for the majority of outbreaks in recent years.
Challenges in developing a norovirus vaccine include the need to stimulate immune responses in the gastrointestinal tract, the site of infection. Despite setbacks, such as HilleVax’s failed clinical trial in infants, companies remain optimistic about the potential for a successful vaccine.
Vaxart is taking a unique approach by developing an oral vaccine in pill form, which could simplify administration and potentially enhance immune response in the GI tract. Moderna’s global phase 3 clinical trial for its mRNA norovirus vaccine is currently underway, with results expected in the coming years.
In the meantime, practicing good hygiene, such as washing hands with soap and water, remains the best defense against norovirus. As the search for an effective vaccine continues, the hope is that a breakthrough will soon provide much-needed protection against this prevalent and harmful virus.
